Evidence map›Paper›PMID 37344608›Full record

ReviewNature protocols2023

Optimizing the Cell Painting assay for image-based profiling.

Beth A Cimini, Srinivas Niranj Chandrasekaran, Maria Kost-Alimova, Lisa Miller, Amy Goodale, Briana Fritchman, Patrick Byrne, Sakshi Garg, Nasim Jamali, David J Logan and 25 more

Abstract readReview
In one paragraph

Review in Nature protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Subcellularly Resolved 3D Translatome in Mouse Oocytes and Early Embryos.bioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. The one-week automated genome-wide optical pooled screen.bioRxiv : the preprint server for biology · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. A scalable approach to resolving variants of uncertain significance.bioRxiv : the preprint server for biology · 2026
    Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Beth A CiminiImaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-9640-9318
Srinivas Niranj ChandrasekaranImaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Maria Kost-AlimovaCenter for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Lisa MillerCenter for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Amy GoodaleGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Briana FritchmanGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Patrick ByrneCenter for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Sakshi GargMerck Healthcare KGaA, Darmstadt, Germany.
Nasim JamaliImaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-1851-6585
David J LoganInternal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA.ORCID 0000-0001-7852-1875
John B ConcannonChemical Biology & Therapeutics Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Charles-Hugues LardeauJanssen Pharmaceutica N.V., Beerse, Belgium.
Elizabeth MouchetAstraZeneca BioPharmaceuticals R&D, Cambridge, UK.
Shantanu SinghImaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-3150-3025
Hamdah Shafqat AbbasiImaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Peter AspesiChemical Biology & Therapeutics Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.ORCID 0000-0002-1987-6446
Justin D BoydInternal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA.
Tamara GilbertInternal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA.
David GnuttBayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany.
Santosh HariharanDiscovery Sciences, Pfizer, Groton, CT, USA.
Desiree HernandezGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Gisela HormelMerck Healthcare KGaA, Darmstadt, Germany.
Karolina JuhaniAstraZeneca BioPharmaceuticals R&D, Cambridge, UK.
Michelle MelansonCenter for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Lewis H MervinAstraZeneca BioPharmaceuticals R&D, Cambridge, UK.
Tiziana MonteverdeAstraZeneca BioPharmaceuticals R&D, Cambridge, UK.
James E PillingAstraZeneca BioPharmaceuticals R&D, Cambridge, UK.
Adam SkepnerCenter for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-9523-2127
Susanne E SwalleyBiogen, Inc., Cambridge, MA, USA.
Anita VrcicCenter for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Erin WeisbartImaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-6437-2458
Guy WilliamsAstraZeneca BioPharmaceuticals R&D, Cambridge, UK.
Shan YuTakeda Development Center Americas, Inc., San Diego, CA, USA.
Bolek ZapiecMerck Healthcare KGaA, Darmstadt, Germany.
Anne E CarpenterImaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA. anne@broadinstitute.org.ORCID 0000-0003-1555-8261

Funding

Extracting rich information from biological imagesR35GM122547 · NIGMS · BROAD INSTITUTE, INC. · PI Anne E. Carpenter · 2017 to 2026
$6.2M
Opera Phenix high-throughput microplate confocal imager for high-content screeningS10OD026839 · OD · BROAD INSTITUTE, INC. · PI WAGNER, BRIDGET K · 2019 to 2019
$1.0M
NIGMS NIH HHS R35 GM122547NIH HHS S10 OD026839
6 · The paper itself

Abstract

In image-based profiling, software extracts thousands of morphological features of cells from multi-channel fluorescence microscopy images, yielding single-cell profiles that can be used for basic research and drug discovery. Powerful applications have been proven, including clustering chemical and genetic perturbations on the basis of their similar morphological impact, identifying disease phenotypes by observing differences in profiles between healthy and diseased cells and predicting assay outcomes by using machine learning, among many others. Here, we provide an updated protocol for the most popular assay for image-based profiling, Cell Painting. Introduced in 2013, it uses six stains imaged in five channels and labels eight diverse components of the cell: DNA, cytoplasmic RNA, nucleoli, actin, Golgi apparatus, plasma membrane, endoplasmic reticulum and mitochondria. The original protocol was updated in 2016 on the basis of several years' experience running it at two sites, after optimizing it by visual stain quality. Here, we describe the work of the Joint Undertaking for Morphological Profiling Cell Painting Consortium, to improve upon the assay via quantitative optimization by measuring the assay's ability to detect morphological phenotypes and group similar perturbations together. The assay gives very robust outputs despite various changes to the protocol, and two vendors' dyes work equivalently well. We present Cell Painting version 3, in which some steps are simplified and several stain concentrations can be reduced, saving costs. Cell culture and image acquisition take 1-2 weeks for typically sized batches of ≤20 plates; feature extraction and data analysis take an additional 1-2 weeks.This protocol is an update to Nat. Protoc. 11, 1757-1774 (2016): https://doi.org/10.1038/nprot.2016.105.

Indexed as

Cell Culture TechniquesImage Processing, Computer-AssistedMicroscopy, FluorescenceMitochondriaSoftware

Identifiers

PMID37344608
PMCPMC10536784

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.